Description

NN1177 TFA (CAS No. 2417491-82-6), also known as NNC9204-1177 TFA, is a synthetic peptide designed as a long-acting co-agonist of the GLP-1 and glucagon receptors. This dual receptor targeting approach aims to enhance weight loss and improve metabolic parameters beyond what is achievable with GLP-1 receptor agonists alone.

In preclinical studies, NN1177 TFA has demonstrated dose-dependent body weight loss in diet-induced obese (DIO) mice, primarily due to fat mass reduction. Additionally, improvements in glucose tolerance have been observed, highlighting its potential for metabolic disorder research.

Manufactured under GMP standards with a purity of 98.66%, NN1177 TFA ensures consistency and reliability for experimental use.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action:
NN1177 TFA functions by simultaneously activating the GLP-1 and glucagon receptors. This dual activation enhances weight loss through increased energy expenditure and reduced food intake, while also improving glucose metabolism.

Research Applications:

• Obesity Research: Investigating the effects of dual receptor agonism on weight loss and fat mass reduction.

• Metabolic Disorder Studies: Exploring the potential of NN1177 TFA in improving glucose tolerance and insulin sensitivity.

  

Side Effects (Research Context Only)

NN1177 TFA is intended for laboratory research use only. In preclinical studies, it has been shown to induce body weight loss and improve glucose tolerance without significant adverse effects. However, as with all experimental compounds, appropriate safety protocols should be followed during handling and administration.

Disclaimer

 is strictly for laboratory research use only. It is not approved for clinical, diagnostic, or therapeutic purposes. Users should adhere to institutional safety guidelines and regulatory requirements when handling this compound.